Actinogen Advances Late-Stage Alzheimer’s Trial as Interim Analysis Supports Continuing XanaMIA Study

Actinogen Medical ( (AU:ACW) ) just unveiled an announcement.

Actinogen Medical reported that its pivotal XanaMIA phase 2b/3 Alzheimer’s disease trial has successfully randomized 247 participants—above the original target—and that an independent Data Monitoring Committee has recommended the study continue unchanged following an interim analysis of unblinded safety and efficacy data, with topline results expected in November 2026. The company is also set to launch an open-label extension phase this quarter to provide up to 25 months of Xanamem treatment and long-term safety and efficacy data, while in parallel advancing manufacturing, commercial planning, partnering discussions, and additional patent filings, underscoring its transition into late-stage development and its bid to secure a competitive foothold in the fast-evolving Alzheimer’s therapeutics landscape.

The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical Limited is an Australian clinical-stage biotechnology company focused on developing Xanamem (emestedastat), an oral therapy targeting brain cortisol to slow progression in Alzheimer’s disease and potentially treat related neurological and psychiatric conditions. The company is positioning itself in the late-stage Alzheimer’s disease treatment market, pursuing global partnering opportunities and strengthening its intellectual property to protect Xanamem from future generic competition.

Average Trading Volume: 5,718,981

Technical Sentiment Signal: Hold

Current Market Cap: A$153.2M

See more insights into ACW stock on TipRanks’ Stock Analysis page.